GlassScriptPhysician profile
Scott J Schutten
NPI 1699079343
$4,742.74
in general payments reported to CMS, 2019-2025
27 companies · $1,329 in 2025
The $1,329 reported for 2025 was more than what 89% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,345 · 2022: $678 · 2023: $556 · 2024: $836 · 2025: $1,329.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,474 · Consulting Fee: $150 · Education: $95.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,474.36 |
| Consulting Fee | $150.00 |
| Education | $95.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,171.09 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $642.10 | 2021-2022 | |
| Biogen, INC. | $478.40 | 2022-2025 | Tysabri, Vumerity, Leqembi |
| Genentech, INC. | $345.83 | 2024-2025 | Ocrevus, Ocrevus Zunovo |
| Tg Therapeutics, INC. | $286.99 | 2023-2025 | |
| Genzyme Corporation | $217.25 | 2022-2025 | |
| Argenx US, INC. | $209.93 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Genentech USA, INC. | $198.32 | 2021-2025 | Ocrevus, Ocrevus Zunovo, Enspryng |
| Biohaven Pharmaceuticals, INC. | $190.16 | 2021 | |
| Celgene Corporation | $189.35 | 2021-2025 | Zeposia |
| Axsome Therapeutics, INC. | $162.21 | 2025 | Symbravo |
| Abbvie INC. | $120.86 | 2021-2023 | |
| Ani Pharmaceuticals, INC. | $100.47 | 2022-2025 | Purified Cortrophin Gel |
| Ucb, INC. | $77.09 | 2024-2025 | Zilbrysq, Rystiggo |
| Allergan, INC. | $61.20 | 2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $39.37 | 2025 | Uplizna |
| Acorda Therapeutics, INC | $37.05 | 2022-2023 | Inbrija, Ampyra |
| Emd Serono, INC. | $33.15 | 2023-2024 | |
| Eisai INC. | $31.55 | 2024-2025 | |
| Otsuka America Pharmaceutical, INC. | $24.70 | 2023 | Nuedexta |
| Pfizer INC. | $22.89 | 2023 | |
| Teva Pharmaceuticals USA, INC. | $21.66 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $19.20 | 2022 | |
| Corium, LLC | $16.75 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $16.43 | 2021 | |
| Janssen Biotech, INC. | $14.85 | 2025 | |
| Horizon Therapeutics Plc | $13.89 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Schutten listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.